158 related articles for article (PubMed ID: 11686505)
41. Cardiac failure and dysrhythmias 6-19 years after anthracycline therapy: a series of 15 patients.
Steinherz LJ; Steinherz PG; Tan C
Med Pediatr Oncol; 1995 Jun; 24(6):352-61. PubMed ID: 7715541
[TBL] [Abstract][Full Text] [Related]
42. Signal-averaged electrocardiography in children with anthracycline-induced cardiomyopathy.
Vaksmann G; Gutierrez R; Duhamel A; Nelken B; Francart C; Kouakam C; Mazingue F; Rey C
Pediatr Cardiol; 2001; 22(6):494-8. PubMed ID: 11894153
[TBL] [Abstract][Full Text] [Related]
43. Non-invasive monitoring of cardiac hemodynamic parameters in doxorubicin-treated patients: comparison with echocardiography.
Villani F; Meazza R; Materazzo C
Anticancer Res; 2006; 26(1B):797-801. PubMed ID: 16739356
[TBL] [Abstract][Full Text] [Related]
44. Does anthracycline administration by infusion in children affect late cardiotoxicity?
Levitt GA; Dorup I; Sorensen K; Sullivan I
Br J Haematol; 2004 Feb; 124(4):463-8. PubMed ID: 14984495
[TBL] [Abstract][Full Text] [Related]
45. Left ventricular function in patients with toxic cardiomyopathy and with idiopathic dilated cardiomyopathy treated with Doxorubicin.
Katamadze NA; Lartsuliani KP; Kiknadze MP
Georgian Med News; 2009 Jan; (166):43-8. PubMed ID: 19202217
[TBL] [Abstract][Full Text] [Related]
46. Dynamic stress echocardiography in asymptomatic patients who received chemotherapy in childhood because of a malignant disease.
Elbl L; Hrstkova H; Chaloupka V; Michalek J
Kardiol Pol; 2003 Mar; 58(3):190-6. PubMed ID: 14513093
[TBL] [Abstract][Full Text] [Related]
47. Corrected QT interval prolongation in anthracycline-treated survivors of childhood cancer.
Schwartz CL; Hobbie WL; Truesdell S; Constine LC; Clark EB
J Clin Oncol; 1993 Oct; 11(10):1906-10. PubMed ID: 8410117
[TBL] [Abstract][Full Text] [Related]
48. Acute cardiomyopathy following a single dose of doxorubicin in a patient with adult T-Cell leukemia/lymphoma.
Farina K; Kalac M; Kim S
J Oncol Pharm Pract; 2021 Jun; 27(4):1011-1015. PubMed ID: 32869692
[TBL] [Abstract][Full Text] [Related]
49. Evaluation of left ventricular function in asymptomatic children about to undergo anthracycline-based chemotherapy for acute leukemia: an outcome study.
Porea TJ; Dreyer ZE; Bricker JT; Mahoney DH
J Pediatr Hematol Oncol; 2001 Oct; 23(7):420-3. PubMed ID: 11878575
[TBL] [Abstract][Full Text] [Related]
50. Anthracycline-induced cardiotoxicity in children with malignancies.
Godoy LY; Fukushige J; Igarashi H; Matsuzaki A; Ueda K
Acta Paediatr Jpn; 1997 Apr; 39(2):188-93. PubMed ID: 9141252
[TBL] [Abstract][Full Text] [Related]
51. Cardiac Toxicity: Using Angiotensin-Converting Enzyme Inhibitors to Prevent Anthracycline-Induced Left Ventricular Dysfunction and Cardiomyopathy.
Kobza C
Clin J Oncol Nurs; 2021 Jun; 25(3):259-266. PubMed ID: 34019025
[TBL] [Abstract][Full Text] [Related]
52. Ventricular-Arterial Coupling in Breast Cancer Patients After Treatment With Anthracycline-Containing Adjuvant Chemotherapy.
Koelwyn GJ; Lewis NC; Ellard SL; Jones LW; Gelinas JC; Rolf JD; Melzer B; Thomas SM; Douglas PS; Khouri MG; Eves ND
Oncologist; 2016 Feb; 21(2):141-9. PubMed ID: 26764251
[TBL] [Abstract][Full Text] [Related]
53. Echocardiographic evaluation of acute cardiotoxicity in the treatment of Hodgkin disease according to the German Hodgkin's Lymphoma Study Group.
Krupicka J; Marková J; Pohlreich D; Kozák T; Línková H; Diehl V;
Leuk Lymphoma; 2002 Dec; 43(12):2325-9. PubMed ID: 12613519
[TBL] [Abstract][Full Text] [Related]
54. Late cardiotoxicity after treatment for a malignant bone tumor.
Postma A; Bink-Boelkens MT; Beaufort-Krol GC; Kengen RA; Elzenga NJ; Schasfoort-van Leeuwen MJ; Schraffordt koops H; Kamps WA
Med Pediatr Oncol; 1996 Apr; 26(4):230-7. PubMed ID: 8600333
[TBL] [Abstract][Full Text] [Related]
55. Impaired exercise capacity and left ventricular function in long-term adult survivors of childhood acute lymphoblastic leukemia.
Christiansen JR; Kanellopoulos A; Lund MB; Massey R; Dalen H; Kiserud CE; Ruud E; Aakhus S
Pediatr Blood Cancer; 2015 Aug; 62(8):1437-43. PubMed ID: 25832752
[TBL] [Abstract][Full Text] [Related]
56. Anthracycline dose in childhood acute lymphoblastic leukemia: issues of early survival versus late cardiotoxicity.
Sorensen K; Levitt G; Bull C; Chessells J; Sullivan I
J Clin Oncol; 1997 Jan; 15(1):61-8. PubMed ID: 8996125
[TBL] [Abstract][Full Text] [Related]
57. [Noninvasive evaluation of chronic cumulative and acute cardiotoxicity induced by anthracycline in children with acute leukemia. Assessment of mainly left ventricular contractile state by M mode echocardiography].
Nakada S; Ogawa S; Hirayama T
Nihon Ika Daigaku Zasshi; 1994 Jun; 61(3):209-19. PubMed ID: 8045995
[TBL] [Abstract][Full Text] [Related]
58. Usefulness of myocardial performance index and biochemical markers for early detection of anthracycline-induced cardiotoxicity in adults.
Dodos F; Halbsguth T; Erdmann E; Hoppe UC
Clin Res Cardiol; 2008 May; 97(5):318-26. PubMed ID: 18193371
[TBL] [Abstract][Full Text] [Related]
59. The clinical value of echocardiography and acoustic cardiography to monitor patients undergoing anthracycline chemotherapy.
Toggweiler S; Odermatt Y; Brauchlin A; Zander T; Müller A; Zuber M; Winterhalder R; Erne P
Clin Cardiol; 2013 Apr; 36(4):201-6. PubMed ID: 23161530
[TBL] [Abstract][Full Text] [Related]
60. Ventricular systolic reserve in asymptomatic children previously treated with low doses of anthracyclines.
Guimaraes-Filho F; Tan D; Braga J; Rodrigues A; Waib P; Matsubara B
Am J Cardiol; 2007 Oct; 100(8):1303-6. PubMed ID: 17920375
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
